Navigation Links
Sunesis to Present at Upcoming Conferences
Date:11/3/2008

SOUTH SAN FRANCISCO, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers, today announced that the company will be presenting at the following upcoming conferences:

Rodman & Renshaw 10th Annual Healthcare Conference

The New York Palace Hotel, New York

Wednesday, November 12, 2008

2:00 p.m. EST

Lazard Capital Markets 5th Annual Healthcare Conference

The St. Regis, New York

Tuesday, November 18, 2008

5:10 p.m. EST

BIO-Europe 2008

m:con Congress Center Rosengarten

Mannheim, Germany

Tuesday, November 18, 2008

9:15 a.m. CET / 3:15 a.m. EST

Interested parties may access a webcast of the Rodman & Renshaw and Lazard Capital presentations by visiting the Sunesis website at http://ir.sunesis.com. A replay of the webcast will be archived on the "Calendar of Events" page in the Investors and Media section of the Sunesis website for two weeks.

About Sunesis Pharmaceuticals

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, voreloxin, in multiple indications to improve the lives of people with cancer. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

SUNESIS and th
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
2. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
3. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
4. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
6. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
7. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
8. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
9. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
10. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
11. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) Centennial Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014  Replikins Ltd. today released new data ... virus. Before the current outbreaks, the mean Ebola Reston ... acids) between 1995 and 2002 was 1.1; the mean ... and sixteen-fold in 2013, thus predicting the current outbreaks ... has been shown to be able to predict outbreaks ...
(Date:7/30/2014)... , July 30, 2014   Wyle ... Fully Integrated Lifecycle Mission Support Services (FILMSS) contract ... (NASA). Under the terms of the contract, Wyle ... at Moffett Field, Calif. In particular, Wyle will ... flight development projects on the International Space Station ...
(Date:7/30/2014)... Vycom announces the addition of Thermax PVC ... Factory Mutual (FM) 4910 fire propagation and smoke generation ... process tools, fume hoods, furniture and cabinetry. These criteria ... wafers used in electronic chip manufacturing. , ... excellent workability and superior aesthetics. It is available in ...
(Date:7/30/2014)... July 30, 2014 Researchers often use ... biology, but such devices can do much more ... As such, researchers have looked to patterned assemblies ... metabolic engineering to characterize – and potentially ... devices are envisioned to recreate animal and human ...
Breaking Biology Technology:Wyle Wins NASA's Fully Integrated Lifecycle Mission Support Services Contract 2Vycom Announces Flametec® Thermax PVC (FM4910 Listed) For a Variety of Clean Room Applications with Excellent Workability and Aesthetics 2UMD Researchers Bridge Gap between Microelectronics, Biological Systems 2UMD Researchers Bridge Gap between Microelectronics, Biological Systems 3UMD Researchers Bridge Gap between Microelectronics, Biological Systems 4
... , , SAN MARINO, ... VRAL) has formed a wholly owned subsidiary called MetaCytoLytics, Inc. ... University of Colorado Professor M. Karen Newell called "metabolic disruption ... to generate energy from glucose or from fatty acids. ...
... , , EMERYVILLE, Calif., ... announced that it has agreed to sell an aggregate of four million ... $30.50 per share and $200 million aggregate principal amount of its 4.00% ... has granted the underwriters 30-day options to purchase up to an additional ...
... rate significantly reduced and Semen Sexing Technology achieves, ... For nine months ended June 30, 2009, Microbix Biosystems Inc. ... The third quarter had a small sales retraction that was ... forecast is for continued growth in sales. , "The 22% ...
Cached Biology Technology:Viral Genetics Creates Subsidiary to Develop Cancer Therapy 2Viral Genetics Creates Subsidiary to Develop Cancer Therapy 3Viral Genetics Creates Subsidiary to Develop Cancer Therapy 4Onyx Pharmaceuticals Announces Pricing of Concurrent Offerings of Four Million Shares of Common Stock and $200 Million Principal Amount of Convertible Senior Notes 2Onyx Pharmaceuticals Announces Pricing of Concurrent Offerings of Four Million Shares of Common Stock and $200 Million Principal Amount of Convertible Senior Notes 3Microbix Sales Grow 22% For Nine Months 2Microbix Sales Grow 22% For Nine Months 3Microbix Sales Grow 22% For Nine Months 4Microbix Sales Grow 22% For Nine Months 5
(Date:7/30/2014)... online today in the journal Scientific Reports , ... and Auroop Ganguly found that while global temperature is ... extremes. For instance, while each year,s average hottest and ... tend to fall within a wider range of potential ... observed. This means that even as overall temperatures rise, ...
(Date:7/29/2014)... methods and applications for imaging and manipulation of the ... were the inspiration behind Neurophotonics , a new ... optics and photonics. , The first issue coincides with ... States, and a special section features articles that lay ... impact that optics and photonics will have on advancing ...
(Date:7/29/2014)... sometimes need to get back to basics. UC ... study the impacts of the bumphead parrotfish ( ... two remote locations in the central Pacific Ocean. ... simulation, McCauley, an assistant professor in the Department ... colleagues sought to understand whether the world,s largest ...
Breaking Biology News(10 mins):Big data confirms climate extremes are here to stay 2SPIE launches Neurophotonics journal with special section on BRAIN Initiative 2SPIE launches Neurophotonics journal with special section on BRAIN Initiative 3Underwater elephants 2Underwater elephants 3
... N.Y. To make paper, manufacturers must break down ... requires large amounts of energy and toxic chemicals like ... biodegradable proteins that accelerate chemical reactions using far less ... the job, in this case xylanases, don,t hold up ...
... the National Institute of Standards and Technology (NIST) and ... a simplified cell membrane to accurately detect and measure ... vaginosis (BV), at extraordinarily low concentrations. The work illustrates ... disease diagnosis. Caused by the bacteria Gardnerella ...
... release is available in German . ... of thousands of neurons in the brain. Nerve growth factors produced ... neurons; however, clinical tests with GDNF have not yielded in any ... Martinsried and their colleagues have now succeeded in demonstrating that GDNF ...
Cached Biology News:Expanding the range of nature's catalysts for industrial applications 2Expanding the range of nature's catalysts for industrial applications 3NIST cell membrane model studied as future diagnostic tool 2Parkinson gene: Nerve growth factor halts mitochondrial degeneration 2Parkinson gene: Nerve growth factor halts mitochondrial degeneration 3
Functionally tested for consistent G-banding of chromosomes....
... BacVector Insect Cell Medium is optimized ... Ea4 Insect Cells. In this protein-free medium, ... 1 * 107 cells/ml with viabilities above ... plaque assays, where color from X-gluc staining ...
... Grace's Insect Medium is formuatled for ... including Sf9 and Sf21 cells. Grace's ... transfectioin because it does not contain ... interfere with transfection. Grace's Insect Medium, ...
TNM-FH Insect Medium 1 liter...
Biology Products: